Pegasys Medication for Hepatitis Infections

Pegasys is a medication used to treat chronic hepatitis B or C infections.

Pegasys FAQ

What is Pegasys used for?

Pegasys is made from human proteins that help the body fight viral infections. Pegasys is used alone or with other medicines to treat chronic hepatitis C in adults and children at least 5 years old. Pegasys is also used to treat chronic hepatitis B when the virus begins to damage the liver in adults and children at least 3 years old.

Is Pegasys available in New Zealand?

Not available in New Zealand Pegasys solution for injection is contained in a disposable glass syringe. The solution is clear and colourless to light yellow. A stainless steel needle is also supplied with the syringe to allow for subcutaneous injection. Active ingredient Inactive ingredients Each pre-filled syringe also contains:

Is Pegasys a cytokine?

Pegasys belongs to a group of agents called cytokines. Interferon alpha produces its anti-cancer effects by stimulating the immune system to help fight the cancer. How is Pegasys typically given (administered)? Pegasys may administered as an injection under the skin (subcutaneous), into the eye, or into the nose (intranasal).

What is a Pegasys syringe?

Pegasys solution for injection is contained in a disposable glass syringe. The solution is clear and colourless to light yellow. A stainless steel needle is also supplied with the syringe to allow for subcutaneous injection. Active ingredient Inactive ingredients Each pre-filled syringe also contains: Pegasys pre-filled syringes are distributed by:

What is another name for Pegasys?

Another name for PEGASYS is peginterferon alfa-2a. PEGASYS is a modified interferon that is different from the interferon made in a person’s body. This modification helps the interferon (PEGASYS) stay in your body for a prolonged time and allows PEGASYS to be injected only once a week. Hepatitis B is more serious for some people than others.

When is Pegasys indicated?

PEGASYS is indicated for the treatment of CHC in pediatric patients 5 to 17 years of age and for the treatment of CHB in pediatric patients 3 to 17 years of age [see Indications and Usage (1.1), (1.2), Dosage and Administration (2.3), (2.5), Clinical Studies (14.1), (14.4)].